Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2024-12-05 Declaration of Voting R…
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 29 novembre 2024" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of November 29, 2024). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF), which mandates monthly disclosure of total voting rights and shares. This type of regular, mandatory disclosure concerning the capital structure and voting rights, often published monthly or quarterly, fits best under the category of general regulatory announcements or specific capital structure updates. Since it is a formal, periodic disclosure of capital structure details mandated by a regulator (AMF), it is a specific type of regulatory filing. While it relates to capital structure, it is not a financing activity (CAP) or a share issue announcement (SHA), but rather a mandatory periodic report on the current state of shares and voting rights. Given the options, this is a specific regulatory disclosure. It is not a full financial report (10-K, IR), an earnings release (ER), or a management report (MDA). It is a formal regulatory disclosure about the share capital structure, which aligns closely with the nature of mandatory filings. Since there isn't a specific 'Share Capital Disclosure' code, and it is a formal regulatory update, it falls under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA) if the changes were the focus, but here it is a status update. Given the context of mandatory monthly reporting on voting rights, RNS is the most appropriate general regulatory fallback, although it is highly specific. However, looking closely at the definitions, it is a report detailing the composition of the capital and voting rights, which is a fundamental aspect of corporate structure reporting. Since it is a formal, periodic regulatory disclosure, RNS is the best fit as a general regulatory filing.
2024-12-05 French
PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024" and explicitly references Article 223-16 of the French Autorité des Marchés Financiers (AMF) regulation. This type of periodic disclosure, detailing the total number of shares and voting rights, is a specific regulatory requirement. It does not fit the definitions for Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). It is a specific regulatory disclosure concerning share capital and voting rights, which is best categorized under the general 'Regulatory Filings' (RNS) as it is a mandatory, periodic disclosure that doesn't match the other specific codes like DVA (which is for *results* of a vote, not the total rights count) or SHA (which is for *changes* like splits/issues, not monthly reporting of the current state). Given the options, RNS serves as the most appropriate catch-all for mandatory, non-financial periodic regulatory updates.
2024-12-05 English
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
Investor Presentation Classification · 1% confidence The document is a press release dated November 27, 2024, detailing a strategic update presented during a webinar titled "Evolving strategic context for phages, Introducing new opportunities." It outlines future revenue projections, development strategies (PTMP and IPT models), and expected profitability milestones (2027). This content is characteristic of an announcement summarizing key strategic and financial outlook points following a presentation or investor event, rather than the full presentation itself (IP) or a formal regulatory filing like a 10-K or IR. Since it is an announcement summarizing a strategic presentation/webinar, it aligns best with an Investor Presentation (IP) if it were the presentation itself, or potentially an Earnings Release (ER) if it contained period results. However, because the core focus is presenting a *new* ambitious development strategy and outlook following a specific event (webinar), and it is structured as a news release, it most closely resembles the type of material often associated with an Investor Presentation (IP) or a high-level strategic update. Given the options, and noting that it is a detailed strategic update presented to investors/analysts, 'Investor Presentation (IP)' is the most fitting category for the *content* being summarized, even though the format is a press release. If the document were purely announcing the *availability* of the presentation, it would be RPA. Since it contains the substance of the strategy update, IP is chosen.
2024-11-27 English
PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapie
Earnings Release Classification · 1% confidence The document is a press release dated November 27, 2024, detailing PHAXIAM Therapeutics' ambitious development strategy, financial outlook (targeting operational profitability in 2027), and announcing a related webinar held on the same day. It discusses business strategy, market context, and future revenue projections based on two models (PTMP and IPT). This content structure—a formal announcement of strategic updates, financial targets, and business direction, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general strategic update. Since it focuses heavily on future financial performance and strategy following a specific event (the webinar), it aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical financial results and related strategic context, even if it's not strictly a quarterly report summary. It is not a full 10-K, an IR, or a simple announcement of a report (RPA/RNS). FY 2024
2024-11-27 French
PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »
Regulatory Filings Classification · 1% confidence The document is a press release dated November 18, 2024, detailing scientific updates presented at a specialized event ('Phagogram Day') concerning PHAXIAM's diagnostic test (Phagogramme) and phage sensitivity results against clinical bacterial strains (S. aureus and P. aeruginosa). It includes key performance indicators (sensitivity percentages) and commentary from management. This format—a formal announcement of recent operational/scientific achievements and data updates, issued outside of the mandatory quarterly/annual reporting cycle—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on presenting results and updates rather than being a full, comprehensive financial report (like 10-K or IR), and it is not a transcript (CT) or a formal investor presentation (IP), the closest fit among the options for a structured announcement of period-specific performance highlights is the Earnings Release (ER) category, even though it's not explicitly tied to a standard fiscal quarter end. However, given the content is a scientific/operational update presented as a formal announcement, and it is not a short notice about a report publication (RPA), it functions as a primary communication of recent performance metrics. If a more specific 'Operational Update' category existed, it would fit there. Lacking that, ER is the best fit for a structured announcement of recent performance data. It is not a DEF 14A (Remuneration), DIRS (Insider Trading), or DIV (Dividend).
2024-11-18 French
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
Regulatory Filings Classification · 1% confidence The document is a press release dated November 18, 2024, detailing the presentation of data regarding PHAXIAM's IVD Phagogram test and phage susceptibility tracking at an event called "Phagogram Day." It highlights key results (sensitivity percentages against S. aureus and P. aeruginosa) and includes quotes from management and boilerplate information about the company and its partners. This structure—a formal announcement of recent operational/scientific achievements and data highlights, issued via press release—is characteristic of an Earnings Release (ER) or a general operational update. Since it focuses on presenting recent performance data (H1 2024 susceptibility tracking) following an event, it aligns best with the 'Earnings Release' definition, which covers the initial announcement of periodical financial/operational results (even if the results here are diagnostic performance metrics rather than traditional GAAP financials). It is not a full 10-K, an Investor Presentation (IP), or a Call Transcript (CT). Given the focus on presenting recent performance data, ER is the most appropriate fit.
2024-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.